Guselkumab Drug Asset Due Diligence Report 2026

This Guselkumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

118

Registered trials

239

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Guselkumab can convert its Monoclonal antibody profile and IL-23p19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Guselkumab (query alias: guselkumab)
Modality / target	Monoclonal antibody; IL-23p19; IL-23p19 inhibitors
Highest global status	Approved
Originator	Janssen Global Services LLC
Active developers	Janssen-Cilag International NV, Janssen Scientific Affairs LLC, Janssen Research & Development LLC

The MCP disease footprint includes Crohn's disease, active moderate, Crohn's disease, active severe, Ulcerative colitis, active moderate. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07616687	Phase 4	Recruiting	210	- Steroid free clinical remission (SFCR) associated with fecal calprotectin < 250 ug/g at Week 48
NCT07654751	Phase 4	Not yet recruiting	10	Guselkumab Concentrations at Steady State in Breast Milk (Q4W Maintenance Regimen)
JPRN-jRCT2031260126	Phase 3	募集前	644	1. Percentage of Participants in Clinical Remission at Week 48 Clinical remission is defined as an stool frequency (SF) subscore of 0 or 1, an rectal bleeding (RB) subscore of 0, and an endoscopy subscore of 0 or 1. Time Frame: At Week 48

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

CNTO1959PSO3018: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Skin of Color Who Have Moderate-to-Severe Plaque Psoriasis and/or Moderate

Phase 3; n=211; evaluation: not stated. Reported fields: Cohort A: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16: Adjusted treatment difference = 74.1(95% CI, 64.4 - 83.7), P-Value = <0.001; Cohort A: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 = 0 Percentage of participants ; Cohort A: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16: Adjusted treatment difference = 74.1(95% CI, 64.4 - 83.7), P-Value = <0.001

Immunogenetic Profiling of Guselkumab for the Treatment of Plaque and Guttate Psoriasis

Phase 4; n=17; evaluation: not stated. Reported fields: Lesional CD4+ T Effector Cells(Mean) = 0.9 Absolute change in % of Th17 cells (Standard Deviation, 23.4); Lesional CD4+ T Effector Cells(Mean) = -5.7 Absolute change in % of Th17 cells (Standard Deviation, 13.5); -

REAL-WORLD ON-LABEL TREATMENT PERSISTENCE THROUGH 24 MONTHS IN BIOLOGIC-NAÏVE AND BIOLOGIC-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS: COMPARISON OF GUSELKUMAB VERSUS TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

Not Applicable; n=2674; evaluation: Positive. Reported fields: Persistence(12-month) = 37.3 % ; Persistence(12-month) = 56.1 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Guselkumab addresses Crohn's disease, active moderate, Crohn's disease, active severe, Ulcerative colitis, active moderate. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-07-09	J&J’s Janssen Doubles Down on Bioinformatics with Celsius Therapeutics Partnership	Approved	Financial terms not disclosed
2017-12-18	Taiho Pharmaceutical Signs a Co-promotion Agreement with Janssen Pharmaceutical K.K. for Guselkumab, a Human Anti-interleukin (IL)-23 Monoclonal Antibody, in Japan	Approved	Financial terms not disclosed
2000-12-01	MorphoSys Starts New Antibody Program With Centocor	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO